DOJ: Johnson & Johnson agrees to pay $2.2B

  • By Pete Yost
    Associated Press November 4, 2013

WASHINGTON (AP) — Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations of promoting three prescription drugs for off-label uses not approved by the Food and Drug Administration, the Department of Justice announced on Monday.

The allegations include paying kickbacks to physicians and pharmacies to recommend and prescribe Risperdal and Invega, both antipsychotic drugs, and Natrecor, which is used to treat heart failure.

The figure includes $1.72 billion in civil settlements with federal and state governments as well as $485 million in criminal fines and forfeited profits.

The agreement is the third-largest U.S. settlement involving a drugmaker, and the latest in a string of legal actions against drug companies allegedly putting profits ahead of patients. In recent years, the government has cracked down on the industry’s aggressive marketing tactics, which include pushing medicines for unapproved uses. While doctors are allowed to prescribe medicines for any use, drugmakers cannot promote them in any way that is not approved by FDA.

Last year British drugmaker GlaxoSmithKline paid a record-setting $3 billion in fines to settle criminal and civil violations involving 10 of its drugs.


blog comments powered by Disqus

Dakota city that grew on fracking reaching out for more retail

Super Bowl of shopping unfolds

Coat giveaway better than any Black Friday sale

Orders for U.S. durable goods rise strong 3 percent in October

Applications for U.S. unemployment benefits fall to 260,000

Deere’s profit tops forecasts even as its sales fall sharply

Consumer spending up a weak 0.1 percent in October

Work begins on outdoor venue at The Meadows

Consumer confidence falls hard in November

Home prices jump in September by most in more than a year